Filing Details

Accession Number:
0001341004-22-000032
Form Type:
13G Filing
Publication Date:
2022-01-31 19:00:00
Filed By:
Danaher Corp /de/
Company:
Telesis Bio Inc.
Filing Date:
2022-02-01
SEC Url:
13G Filing
Ownership Summary

Please notice the below summary table is generated without human intervention and may contain errors. Please refer to the complete filing displayed below for exact figures.

Name Sole Voting Power Shared Voting Power Sole Dispositive Power Shared Dispositive Power Aggregate Amount Owned Power Percent of Class
Danaher Corporation 2,294,157 0 2,294,157 0 2,294,157 7.8%
Danaher Innovation Center 2,294,157 0 2,294,157 0 2,294,157 7.8%
Filing

UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C.  20549
 
SCHEDULE 13G
 
Under the Securities Exchange Act of 1934
 
(Amendment No.)*
 
Codex DNA, Inc.
(Name of Issuer)
 
Common Stock, par value $0.0001 per share
(Title of Class of Securities)
 
192003101
(CUSIP Number)
 
December 31, 2021
(Date of Event Which Requires Filing of this Statement)
 
 
Check the appropriate box to designate the rule pursuant to which this Schedule is filed:
 
 
Rule 13d-1(b)
 
 
Rule 13d-1(c)
 
 
Rule 13d-1(d)
 
 *The remainder of this cover page shall be filled out for a reporting person’s initial filing on this form with respect to the subject class of securities, and for any subsequent amendment containing information which would alter disclosures provided in a prior cover page.
 
The information required in the remainder of this cover page shall not be deemed to be “filed” for the purpose of Section 18 of the Securities Exchange Act of 1934 (“Act”) or otherwise subject to the liabilities of that section of the Act but shall be subject to all other provisions of the Act (however, see the Notes).
 
 
CUSIP No.: 192003101
 


1.
NAME OF REPORTING PERSON
 
Danaher Corporation
2.
CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP
 
 
(a) 
 
 
(b) 
3.
SEC USE ONLY
 
4.
CITIZENSHIP OR PLACE OF ORGANIZATION
Delaware
Number of
Shares
Beneficially 
Owned by
Each
Reporting
Person With: 
 
5.
SOLE VOTING POWER
 
2,294,157
6.
SHARED VOTING POWER
 
0
7. 
SOLE DISPOSITIVE POWER
 
2,294,157
8.  
SHARED DISPOSITIVE POWER
 
0
9.
AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON
 
2,294,157
10. 
CHECK BOX IF THE AGGREGATE AMOUNT IN ROW (9) EXCLUDES CERTAIN SHARES
11.
PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (9)
 
7.8% 
12. 
TYPE OF REPORTING PERSON
 
CO 
CUSIP No.: 192003101
 


1.
NAME OF REPORTING PERSON
 
Danaher Innovation Center LLC
2.
CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP
 
 
(a) 
 
 
(b) 
3.
SEC USE ONLY
 
4.
CITIZENSHIP OR PLACE OF ORGANIZATION
Delaware
Number of
Shares
Beneficially 
Owned by
Each
Reporting
Person With: 
 
5.
SOLE VOTING POWER
 
2,294,157
6.
SHARED VOTING POWER
 
0
7. 
SOLE DISPOSITIVE POWER
 
2,294,157 
8.  
SHARED DISPOSITIVE POWER
 
0
9.
AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON
 
2,294,157
10. 
CHECK BOX IF THE AGGREGATE AMOUNT IN ROW (9) EXCLUDES CERTAIN SHARES
11.
PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (9)
 
7.8% 
12. 
TYPE OF REPORTING PERSON
 
OO 


Item 1.
 

(a)
Name of Issuer:
 
The name of the issuer is Codex DNA, Inc. (the “Issuer”).
 

(b)
Address of Issuer’s Principal Executive Offices:
 
The address of the Issuer’s principal executive offices is:

Codex DNA, Inc.
9535 Waples Street, Suite 100
San Diego, CA 92121-2993
 
Item 2.
 

(a)
Name of Person Filing:
 
This schedule is filed by Danaher Corporation, a Delaware corporation (“Danaher”), and its subsidiary, Danaher Innovation Center LLC, a Delaware limited liability company (“DIC”).  Danaher and DIC are collectively referred to herein as the “Reporting Persons.”


(b)
Address of Principal Business Office:
 
The address of the principal office of each of the Reporting Persons is:

2200 Pennsylvania Avenue, NW
Suite 800W
Washington, DC 20037-1701
 

(c)
Citizenship:
 
Danaher is a Delaware corporation.  DIC is a Delaware limited liability company.
 

(d)
Title of Class of Securities:
 
Common Stock, par value $0.0001 per share (the “Common Stock”)
 

(e)
CUSIP Number:
 
192003101
 
Item 3.
Statement filed pursuant to §§240.13d-1(b) or 240.13d-2(b) or (c).

Not applicable. 
 
Item 4.
Ownership.
 

(a)
Amount beneficially owned: See Item 9 of the cover page for each Reporting Person.
 


(b)
The Reporting Persons may each be deemed the beneficial owner of 7.8% of the Common Stock outstanding, based on 29,307,199 shares of Common Stock outstanding, as reported in the Issuer’s Quarterly Report on Form 10-Q filed on November 10, 2021.
 

(c) (i)           Sole power to vote or direct the vote:
 
See Item 5 of the cover page for each Reporting Person.
 

(ii)
Shared power to vote or direct the vote:
 
See Item 6 of the cover page for each Reporting Person.
 

(iii)
Sole power to dispose or direct the disposition:  
 
See Item 7 of the cover page for each Reporting Person.
 

(iv)
Shared power to dispose or direct the disposition:  
 
See Item 8 of the cover page for each Reporting Person.
 
Item 5.
Ownership of Five Percent or Less of a Class.
 
Not applicable.
 
Item 6.
Ownership of More than Five Percent on Behalf of Another Person.
 
Not applicable.
 
Item 7.
Identification and Classification of the Subsidiary Which Acquired the Security Being Reported on By the Parent Holding Company or Control Person.
 
Not applicable.
 
Item 8.
Identification and Classification of Members of the Group.
 
Not applicable.
 
Item 9.
Notice of Dissolution of Group.
 
Not applicable.
 
Item 10.
Certifications.
 
Not applicable.
SIGNATURE
 
After reasonable inquiry and to the best of my knowledge and belief, I certify that the information set forth in this statement is true, complete and correct.
 
Dated: February 1, 2022

 
 
DANAHER CORPORATION
 
 
 
 
 
By:
/s/ Jose-Carlos Gutierrez-Ramos
 
Name:
Jose-Carlos Gutierrez-Ramos
 
Title:
Senior Vice President and Chief Science Officer
   
   
 
DANAHER INNOVATION CENTER LLC
 
 
 
 
 
By:
/s/ Jose-Carlos Gutierrez-Ramos
 
Name:
Jose-Carlos Gutierrez-Ramos
 
Title:
President

EXHIBIT INDEX
Exhibit No.
 
Description
     
99.1
 
Joint Filing Agreement